Kai‐Keen Shiu
YOU?
Author Swipe
View article: Treatment-related adverse events as a source of financial hardship in young adults with breast cancer: a qualitative study
Treatment-related adverse events as a source of financial hardship in young adults with breast cancer: a qualitative study Open
View article: 477TiP A randomised phase II study of zimberelimab ± domvanalimab immunotherapy in resectable mismatch repair deficient (dMMR) gastric and gastroesophageal junctional (G/GOJ) adenocarcinoma (ZODIAC)
477TiP A randomised phase II study of zimberelimab ± domvanalimab immunotherapy in resectable mismatch repair deficient (dMMR) gastric and gastroesophageal junctional (G/GOJ) adenocarcinoma (ZODIAC) Open
View article: A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP)
A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP) Open
Background Cancer of Unknown Primary (CUP) is an aggressive malignancy with limited treatment options and poor patient outcomes. In most cases, the primary site remains elusive, limiting therapeutic options to non-specific chemotherapy. Th…
View article: The Role of Social Support in Buffering the Financial Toxicity of Breast Cancer: A Qualitative Study of Patient Experiences
The Role of Social Support in Buffering the Financial Toxicity of Breast Cancer: A Qualitative Study of Patient Experiences Open
Background/Objectives: Financial distress from the direct and indirect costs of cancer treatment is a critical issue for many patients with breast cancer, particularly those from underserved populations who may be more vulnerable to financ…
View article: Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer
Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer Open
The markedly improved overall survival with fluoropyrimidines in patients with gastrointestinal cancer significantly outweighs the small risk of cardiac arrhythmia and arrest. Oncologists should take this into consideration for decision ma…
View article: Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study Open
Nivolumab/ipilimumab did not improve disease-free survival compared with chemotherapy in patients with ypN+ and/or R1 gastro-oesophageal adenocarcinoma following neoadjuvant chemotherapy and surgery.
View article: Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series
Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series Open
Bowel obstruction associated with immunotherapy response may represent a rare treatment-related complication in dMMR CC. Clinicians must recognise this safety signal and share experience to maintain patient safety.
View article: Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies
Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies Open
Objective Fluoropyrimidine chemotherapy is a first-line treatment for many gastrointestinal (GI) cancers, however, cardiotoxicity concerns may limit administration in patients with pre-existing cardiovascular disease (CVD). This study inve…
View article: Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study Open
PURPOSE Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination with pembrolizumab improves outcomes compared with standar…
View article: Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies
Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies Open
Background: Cholangiocarcinoma (CCA) is associated with poor outcomes and limited treatment options, leading to increased use of targeted therapies for its management. Here, we performed one of the largest single-centre reviews evaluating …
View article: Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary
Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary Open
Background Biomarkers of systemic inflammation have been shown to predict outcomes in patients with cancer of unknown primary (CUP). We sought to validate these findings in patients with confirmed CUP (cCUP) and explore their role alongsid…
View article: Genetic and immune landscape evolution in <scp>MMR‐</scp> deficient colorectal cancer
Genetic and immune landscape evolution in <span>MMR‐</span> deficient colorectal cancer Open
Mismatch repair‐deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens, which make these tumours immunogenic and many respond to immune checkpoint inhibitors. The MMRd hypermutator phenotype may also promote intratumour hete…
View article: The immunomodulatory role of IDO1-Kynurenine-NAD+ pathway in switching cold tumor microenvironment in PDAC
The immunomodulatory role of IDO1-Kynurenine-NAD+ pathway in switching cold tumor microenvironment in PDAC Open
Pancreatic ductal adenocarcinoma (PDAC) is the most common exocrine tumor of the pancreas characterized by late diagnosis, adverse overall 5-year survival, a higher propensity for metastatic disease, and lack of efficacy of systemic therap…
View article: O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study
O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study Open
View article: O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
O-3 Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer Open
View article: LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study
LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study Open
View article: Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer
Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer Open
PDF file - 3567K
View article: Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer
Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer Open
PDF file - 3567K
View article: Press Conference from Functional Viability Profiles of Breast Cancer
Press Conference from Functional Viability Profiles of Breast Cancer Open
Press Conference from Functional Viability Profiles of Breast Cancer
View article: Data from Functional Viability Profiles of Breast Cancer
Data from Functional Viability Profiles of Breast Cancer Open
The design of targeted therapeutic strategies for cancer has largely been driven by the identification of tumor-specific genetic changes. However, the large number of genetic alterations present in tumor cells means that it is difficult to…
View article: Data from Functional Viability Profiles of Breast Cancer
Data from Functional Viability Profiles of Breast Cancer Open
The design of targeted therapeutic strategies for cancer has largely been driven by the identification of tumor-specific genetic changes. However, the large number of genetic alterations present in tumor cells means that it is difficult to…
View article: Press Conference from Functional Viability Profiles of Breast Cancer
Press Conference from Functional Viability Profiles of Breast Cancer Open
Press Conference from Functional Viability Profiles of Breast Cancer
View article: Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer Open
The phase 3 KEYNOTE‐177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite‐instability‐high (MSI‐H)/mismatch‐repair‐deficient (dMMR) metastatic colore…
View article: Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study Open
View article: Mutation Rate Evolution Drives Immune Escape In Mismatch Repair-Deficient Cancer
Mutation Rate Evolution Drives Immune Escape In Mismatch Repair-Deficient Cancer Open
SUMMARY Mutation rate optimisation drives evolution and immune evasion of bacteria and lentiviral strains, including HIV. Whether evolving cancer lineages similarly adapt mutation rates to increase tumour cell fitness is unknown. Here, by …
View article: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer
Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer Open
Mismatch repair deficient colorectal cancers have high mutation loads and many respond to immune checkpoint-inhibitors. We investigated how genetic and immune landscapes co-evolve in these tumors. All cases had high truncal mutation loads.…
View article: Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer Open
Background: Complex innovative design trials are becoming increasingly common and offer potential for improving patient outcomes in a faster time frame. FOCUS4 was the first molecularly stratified trial in metastatic colorectal cancer and …
View article: Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors Open
View article: PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177
PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177 Open
View article: O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer Open